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Energy homeostasis is achieved by the integration of pe-
ripheral metabolic signals by the neural circuits involving
speciﬁc hypothalamic nuclei and brain stem regions. These
neuralcircuitsmediatemanyoftheeffectsoftheadipocyte-
derived hormone leptin and gut-derived hormone ghrelin.
The former is strongly anorexigenic while the latter is
the only orexigenic agent active when administered by a pe-
ripheral route. Abnormal regulation of these 2 antagonistic
regulatory peptides in patients with schizophrenia could
play a role in the impairment in the regulation of food in-
takeandenergybalance.Thisbibliographicalanalysisaims
to compare 27 prospective and cross-sectional studies pub-
lished on circulating leptin and ghrelin levels during acute
and chronic administration of antipsychotics treatment, es-
pecially atypical ones. Fasting morning leptin levels of
schizophrenic patients increase rapidly in the ﬁrst 2 weeks
after atypical antipsychotic (AAP) treatment (mostly olan-
zapine and clozapine) and remain somehow elevated after
that period up to several months. On the contrary, conven-
tional antipsychotics (such as haloperidol) do not interfere
with leptin levels. In contrast to leptin, fasting morning
ghrelin levels decrease during the ﬁrst few weeks after
the beginning of AAPs treatment while they increase in
the longer run. Surprisingly, body weight gain and cor-
relations between the variation of these 2 peptides and
adiposity and metabolism-related parameters such as
the body mass index and abdominal perimeter were not
systematically considered. Finally, an objective evaluation
of feeding behavior during antipsychotic treatment remains
to be determined.
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Introduction
Atypical antipsychotics (AAPs) became the first-line
treatment in schizophrenia and many other mental disor-
ders due to better efficacy and more favorable side effect
profile than the first-generation antipsychotics. As the
number of AAP-treated patients and available data,
higher incidence of significant weight gain (WG) was ob-
served, with the higher risk associated with clozapine and
olanzapine, followed by quetiapine and risperidone.
1–3
High blood glucose has also been reported with the
use of AAP treatment particularly with clozapine and
olanzapine.
4
The higher risk of cardiovascular disease, leading to
enhanced morbidity, important economic cost, and mor-
tality (reducing quality of life [QOL] and lower compli-
ance to treatment) can be linked to the obesitogenic and
diabetogenic capacity of these drugs.
5–7
The mechanisms by which some AAP drugs contribute
to WG and cardiovascular risk are still poorly under-
stood. It is believed that the interaction is probably mul-
tifactorially determined (eg, Brady
8): increased appetite,
energyintakeandstorage,metabolicandendocrinealter-
ations, reduced energy expenditure and increased utiliza-
tion, as well as lower physical activity (eg, Zipursky
9 and
Levin and Rezvani
10) have all been involved in AAP-
induced WG. Many neuropeptides and hormones are
involved in energy homeostasis and body weight (BW)
regulation. Among those, leptin and ghrelin appears to
play a crucial role in the energy balance (modulation
of hunger and satiety) and appetite (food choice), during
treatment with some AAP.
11,12
It has been suggested that antipsychotics (AP) interact
with the complex system of neurotransmitters, neuropep-
tides, and other modulators in brain neuronal circuits in-
volving the hypothalamus and brain stem where
aneuropeptidergic networkmediatestheactions ofleptin
and ghrelin to provoke disturbances in energy homeosta-
sis, endocrine alterations, and BW control.
13,14
The distribution of adipose tissue within the body is
recognized as a key factor influencingthe effect ofincreas-
ing weight on health. Several studies have demonstrated
a link between abdominal adiposity and overall mortality,
with visceral adiposity associated with an increase risk of
diseases as dyslipidemia and glucose intolerance.
15
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1189The discovery in 1994 by Zhang and associates
16 of
the adipocyte-derived circulating hormone leptin (from
the Greek leptos, meaning thin) changed the status of the
adipocyte from a mere storage compartment to a new
endocrine organ. Leptin is the protein product of the
obese (ob) gene located on chromosome 7 (7q31.3), a
highly hydrophilic 167 amino acid protein with an
N-terminal secretory signal sequence. Circulating leptin
is found in human serum either in its free form as a
16-kDa protein or in its sOB-R (soluble form of the
leptin receptor) bound form.
17 Leptin is produced by
adipocytes in proportion to fat stores. Thus, it directly
communicates the state of energy reserves to the brain in
order to control feeding and metabolism, modulate
satiety, energy intake, and energy expenditure. The effects
of leptin in food intake and energy homeostasis are
central and mediated via a network of orexigenic and
anorexigenic neuropeptides containing neurons located
in the mediobasal (tuberoinfundibular) portion of the
hypothalamus (see figure 1). Leptin directly activates
proopiomelanocortin (POMC) cells in the arcuate nucleus
to increase the release of melanocortin peptides, including
the POMC product a-melanocyte–stimulating hormone
(a-MSH). Melanocortins (MCs) inhibit food intake and
regulate metabolism, energy storage, insulin secretion,
andgastrointestinalmotilitypredominantlyviaprojections
to MC4 receptor neurons. Moreover, leptin also directly
inhibits arcuate neurons, which produce agouti-related
protein (AgRP) and neuropeptide Y (NPY). AgRP is an
endogenous antagonist of a-MSH at MC4 receptors
and, peripherally, has neuroendocrine functions involved
in food consumption and weight regulation.
18,19 NPY is
a potent orexigenic agent when injected intracerebrally.
Leptin receptors are also present in the ventrotegmental
area (VTA) and leptin targets dopaminergic and gamma-
aminobutyric acid neurons of in this region critical to
brain reward circuits, inducing phosphorylation of signal
transducer and activator of transcription-3.
20 Direct
administration of leptin in the VTA also caused decreased
food intake (see figure 1).
21 Conversely, long-term RNAi-
mediated knockdown of leptin receptor (ObR) in the
VTA led to increased food intake, locomotor activity,
and sensitivity to highly palatable food. These data
support a critical role for VTA ObR in regulating
feeding behavior and provide functional evidence for
direct peripheral metabolic signaling on VTA dopamine
neurons.
Peripheral administration of leptin reduces appetite
and feeding while leptin deficiency (both mice and
humans with mutations in the leptin or leptin receptor
genes) causes extreme obesity and increased thermogen-
esis (eg, Considin et al
22 and Maffei et al
23). The rate of
leptin production is related to adiposity; it is secreted in
a pulsatile fashion but without a marked circadian
rhythm. It is influenced by gender, women having mark-
edly higher leptin concentrations than men for any given
degree of fat mass.
17 It is decreased with older age, with
physical activity and its secretion is stimulated by insulin,
but a large portion of interindividual variability in leptin
concentration is independent of body fat mass.
24
Beside the very rare case of genetic leptin deficiency,
the vast majority of obese humans have high plasma lep-
tinconcentrationsrelatedtothesizeofadiposetissue,but
this elevated leptin signal does not induce the expected
responses (ie, a reduction in food intake and an increase
in energy expenditure), thus suggesting that most obese
human subjects are resistant to the effects of endogenous
leptin.
25
In 1999, 5 years after the discovery of leptin, a novel
gastrointestinal peptide hormone was characterized
and named ghrelin (from the Sanskrit ghre, to grow),
26
based on its ability to bind to the growth hormone
(GH) secretagogue receptor (GHS-R) and its capacity
toreleaseGH.Thegenecodingforhumanpreproghrelin,
growth hormone receptor ligand, is located on chromo-
some 3 (3p25-26). This 28 amino acid peptide has the par-
ticularity to present with an n-octanoyl modification on
Ser 3, which makes it the natural endogenous ligand of
the GHS-R and allows it to act as potent appetite-stim-
ulating hormone (eg, Tschop
27) probably by directly
stimulating the activity of neurons expressing AgRP/
NPY production (and possibly orexins) while indirectly
inhibiting POMC and corticotropin releasing hormone
neuronal activities.
28 GHS-R are also located in the
VTA, and ghrelin administration in this ventral mesence-
phalic region stimulates locomotor activity and increases
extracellular concentration of dopamine in the nucleus
accumbens.
29Ghrelin is mainly produced and released
by the P/D1 cells, an enteroendocrine cells in the stom-
ach, which also express the vesicular monoamine trans-
porter 2, suggesting a role of monoaminergic
transmission in the regulation of ghrelin.
30 Ghrelin
also stimulates preadipocyte differentiation, increases
the body fat mass, and inhibits the anorexigenic effect
of leptin. Circulating ghrelin and leptin are inversely
Fig. 1. Neural Circuits Involved in the Integration of Peripheral
MetabolicSignalsControllingHomeostasis.Leptinandghrelinact
antagonistically within the hypothalamic circuits regulating energy
metabolism. They also interact in the brain stem satiety center to
regulate the dorsal vagal complex in the basal mesencephalon on
reward-seeking mechanism.
20,21,30
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Moore
28), but this remains controversial in humans.
This food intake–stimulatory signal has opened a new
era of understanding of anabolism feeding behavior and
nutritional homeostasis for GH secretion and gastrointes-
tinal motility through gut-brain interactions (see figure 1).
Tschop et al
27 investigated the possible involvement of
ghrelin in the pathogenesis in human obesity in a popula-
tion of 30 subjects (15 Caucasian: 7 lean and 8 obese and
15 Pima Indians: 7 lean and 8 obese). They observed that
fasting plasma concentrations of octanoylated ghrelin
wasnegativelycorrelatedwithpercentbodyfatandleptin
levels.
The secretion of ghrelin by the stomach depends
largely on the nutritional state. Ghrelin levels show pre-
prandial increases and postprandial decreases. In addi-
tion, ghrelin levels show a diurnal variation and seem
to decrease in older age. It is higher in women and cor-
relates negatively with body mass index (BMI) and GH
while glucose and insulin seem to decrease its level.
31
In 2 studies of a large sample of population-based co-
hort,ametabolicsyndrome(MS)wasassociatedwithlow
ghrelin levels, suggesting a relationship of ghrelin in the
metabolic disturbances of MS: waist circumference,
blood pressure, high density lipoprotein cholesterol,
and triglycerides (low ghrelin was a significant predictor
of MS).
32,33
Thus, both leptin and ghrelin play major roles in the
control system for energy balance in humans. However,
leptin appears more involved in long-term regulation of
energy balance, being released into the circulatory system
as afunction of energy stores, whereas ghrelincan also be
considered as a fast-acting hormone, of which the circu-
latory levels show clear meal-related changes. Based on
genetically modified rodent models, another difference
is that, in contrast to leptin, ghrelin does not seem to
be critical for normal appetite and growth.
24 However,
it is not yet fully understood whether the variations in
circulating leptin and ghrelin concentrations are a direct
effect of AAP administration or secondary to the AAP-
induced WG.
Therefore, the main goal of this review was to analyze
a large panel of recently published studies evaluating the
impact of antipsychotic in leptin and ghrelin blood levels;
it could exert potent disturbing effects in food intake atti-
tudes, inducing BW control problems.
Methods
A literature search (MEDLINE/PubMed) was under-
taken for the year ranging from 1998 (where leptin
was first to be analyzed in schizophrenic patient with
WG) to June 2007. The following key words were
cross-referenced: ‘‘leptin,’’ ‘‘ghrelin,’’ ‘‘schizophrenia,’’
and ‘‘antipsychotic.’’ The clinically relevant reports
(cross-sectional and prospective studies), dealing with
the blood variation of leptin and ghrelin in adult schizo-
phrenic patients treated with atypical and conventional
antipsychotics, were analyzed. All applicable references
wereexaminedandscrutinizedby2psychiatristreviewers
(M.F.P. and O.S.). To achieve a legitimate and workable
summary of findings, data from prospective vs cross-
sectional studies were separated and ranked according
to variations in leptin blood level, ghrelin blood level,
and both parameters in adult patients treated with anti-
psychotic drugs. This selection process resulted in 23
relevant articles concerning modification of leptin in
schizophrenic or schizoaffective patients with AAP and
conventional neuroleptic (17 prospective and 6 cross-
sectional studies) and 8 articles about ghrelin (5 prospec-
tive and 3 cross-sectional studies). Four studies evaluated
both leptin and ghrelin levels.
Commentary
Leptin
Table 1 summarizes 17 prospective and 6 cross-sectionals
studies which evaluated the effects of AP on leptin con-
centration. It is organized according to the treatments
given because our main objective was to evaluate the im-
pact of antipsychotic treatments on circulating regula-
tory peptides over a period of time.
Concerning prospective studies, Bromel et al
34 evalu-
ated 9 schizophrenic patients and 3 schizoaffective disor-
der patients, who were assigned to monotherapy with
clozapine (only 8 were additionally treated with conven-
tional neuroleptics and other psychotropic drugs). These
authors reported that serum leptin levels (SLLs) prior to
initiation of clozapine treatment differed significantly
from levels measured afterward (P < .0001) with concen-
trations at least doubling in 8 clozapine-treated psychotic
patients by week 2 (P = .023) vs baseline and no signif-
icant changes up to the 10th week vs week 2 (P = .126). In
3 patients, leptin levels remained similar to baseline.
Moreover, the net differences in BW and BMI between
baseline and week 2 revealed positive correlations (r =
.3 and .75, respectively) to the relative increases in the
SLL at week 2.
In 2002, Monteleone et al
35 prospectively measured
plasma leptin levels (PPLs) in 22 chronic resistant schizo-
phrenic patients treated with clozapine in monotherapy;
blood samples were taken at baseline and after 1, 2, 4, 6,
8, 12, 16, 24, and 32 weeks. These authors found that
plasma leptin concentrations doubled after only 2 weeks
of clozapine administration. By the end of week 4, leptin
levels abruptly fell to levels more strictly related to BW
changes and, subsequently, progressively rose up to the
32nd week of treatment, paralleling the progressive in-
crease of WG. Significant differences were observed be-
tween men and women in the mean baseline values in
plasma leptin (5.0 6 3.4 vs 14.7 6 7.7 ng/ml), but it
did not differ over time.
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Authors
Washout
Period (d) Drug
Number of
Patients
Duration
(wk)
Mean Age
(y) 6 SD Leptin Modiﬁcations
Prospective studies
Bromel et al
34 NA CLZ 12 (6 w/6 m) 10 31(22–44) W2 vs B: b, W10 vs
W2: NS
Monteleone et al
35 14 CLZ 22 (9 w/13 m) 32 (26–61) W2 vs B:b, W32 vs
B: b,W 4v sW 2 :a
Kivircik et al
36 2–5 CLZ 19 (11 w/8 m) 10 37.4 6 10.5 W4 vs B: NS, W10 vs
B: NS
Theisen et al
12 NA CLZ 12 (6 w/6 m) 10 31 6 7.1 W2 vs B: b, W10 vs
B: b, W10 vs W2: NS
Popovic et al
41 Switch CLZ/RISP 18 (9 w/9 m) 12 28.8 6 1.6 W12 vs B: b
Graham et al
37 NA OLZ 09(3 w/6 m) 12 21.5 (20.8–27.3) W12 vs B: NS
Murashita et al
38 NA OLZ 7 (3 w/4 m) 26 46.3 6 15.7 W26 vs B: b
Hosojima et al
11 28 OLZ 13 (4 w/9 m) 4 37 (20–56) W4 vs B: b
Wang et al
39 NA OLZ 09 (4 w/5 m) 2 35 6 10 H4 vs B: b,W 2v s
B: NS
Baptista et al
40 Switch OLZ 60 (26 w/34 m) 16 46.5 6 10.7 W8 vs B: b, W16
NS vs B
Eder et al
42 3; 5 naive
patients
OLZ 10 (2 w/8 m) 8 30.4 6 7W 8 v s B : b
HC 10 W8 vs B: NS
Ebenbichler et al
43 3 OLZ 14 10 W10 vs B: b
HC 14 W8 vs B: NS
Atmaca et al
44 14 OLZ 21(7 w/14 m) 6 30.4 6 7.8 W6 vs B: b
HC 21 W6 vs B: NS
Atmaca et al
45 14 OLZ 15 6 29.2 6 11.8 W6 vs B: b
QUET 15 28.6 6 11.3 W6 vs B: b
HAL 15 27.4 6 10.6 W6 vs B: NS
Kraus et al
46 NA CLZ 11 (7 w/4 m) 4 37 6 19 W2 vs B: b,W 4v s
W2: NS
OLZ 08 (5 w/3 m) 26 6 6W 2 v s B : b,W 4v s
W2: NS
HAL 13 (7 w/6 m) 36 6 16 W2 vs B: b,W 4v s
W2: NS
HC 12 (7 w/5 m) 30 6 12 W2 vs B: NS, W4 vs
B: NS
Fitzgerald et al
48 NA CLZ/RISP 22 (w) 34.6 6 8.9 W12 vs B: b
Zhang et al
47 Naive
patients
CLZ/RISP/CPZ 46 (19 w/27 m) 10 26.5 6 6.6 W10 vs B: b
HC 38 (16 w/22 m)
Cross-sectional studies
Melkerson et al
50 OLZ 14 (7 w/7 m) 20 (10–72) 44 (30–60) OLZ vs CLZ vs CONV:
NS CLZ 14 (7 w/7 m) 156 (26–384) 35 (26–47)
CONV 19 (9 w/10 m) 156 (15–104) 42 (28–72)
Herran et al
51 CLZ 5 26 38.2 6 11.2 NS vs HC
OLZ 7 NS vs HC
RISP 5 NS vs HC
CONV 34 NS vs HC
HC 59 38.1 6 9.6
Haag et al
52 CLZ 41 (20 w/21 m) 145 (124–171) 41 (39–44) w vs HC: b, m vs HC:
NS
CONV 62 (24 w/38 m) 452 (369–530) 49 (46–51) w vs HC: b, m vs HC:
NS
HC 189 46 (26–65)
Haupt et al
53 OLZ/RISP/CONV 27 (12–104) 38.16 8.3 NS vs HC
HC 124
Murashita et al
54 RISP 15 (10 w/5 m) 26 40.8 6 11.8 b vs HC
HC 25
Note: NA, not available; CLZ, clozapine; w, women; m, men; W, week; B, baseline; NS, nonsignificant, P > .05; RISP, risperidone;
OLZ, olanzapine; H, hour; HC, healthy control; QUET, quetiapine; HAL, haloperidol; CPZ, chlorpromazine; CONV, conventional.
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36 reported on 19 in- and outpatients with
schizophrenia who completed 10 weeks of treatment with
clozapine that the analysis of variance did not reveal any
significant change in leptin among baseline and the
patient gained 5% of their BW (baseline: 11.87 6 9.70
ng/ml, weight: 65.3 6 15.9 kg vs week 4: 11.56 6 10.80
ng/ml vs week 10: 13.11 6 10.08 ng/ml, weight: 68.6 6
16.4 kg). The increase in BMI was significant (P <
.001), but the variation in SLL was not correlated with
the change in BW and in BMI.
Theisen et al
12 investigated SLL and BMI in 12
patients with schizophrenia or schizoaffective disorders
over a 10-week period after initiation of clozapine treat-
ment (8 patients were additionally treated with other AP,
benzodiazepines, and/or antidepressant). The investiga-
tors observed that both SLL and BMI increased signifi-
cantly from baseline to week 2, and this increase stayed
stable in week 10 (baseline: 8.3 6 6.5 ng/ml vs week 2:
13.8 6 11.9 ng/ml, P < .05, vs week 10: 13.6 6 11.4
ng/ml, and for BMI, baseline: 25.2 6 4.8 kg/m
2 vs
week 10: 26.5 6 5.0 kg/m
2, P < .05).
Concerningolanzapinetreatment,Grahametal
37eval-
uated anthropomorphic measures and leptin levels in the
first and last visits (12 weeks apart) in 9 patients after
a first psychotic episode. They did not observe any sig-
nificant variation on SLL: 5.16 (range 3.90–7.42) to
7.58 ng/ml (range 5.27–14.69), and median change was
not significant (P < .16) but a significant variation in
BW (P = .004).
In contrast, Murashita et al
38 compared metabolic
parameters before and after 6-month administration of
olanzapine in 7 Japanese patients with schizophrenia,
and the investigators reported that the SLL were signif-
icantly increased (baseline: 10 6 1.9 ng/ml vs week 26:
12.9 6 3.4 ng/ml, P = .028), but BW and BMI did not
vary significantly after 6 month of treatment.
Hosojima et al
11 recruited 13 patients with schizo-
phrenia (6 patients were AP naive) who received a
monotherapy of olanzapine for 4 weeks. SLL increased
from baseline to week 4 (baseline: 3.2 6 2.7 ng/ml vs
week 4: 4.6 6 4.1 ng/ml, P = .02), and the patients had
gained 1.7 kg of their baseline weight at week 4 (P = .01).
Wang et al
39 were the first to monitor the very early
changes in leptin levels at baseline, after 2 h, 4 h, 3, 7,
and 14 days olanzapine initiating treatment in 9 patients
withschizophrenia.Theseinvestigatorsobservedasignif-
icant increment in the PLLs as soon as at the fourth hour
after the beginning of the treatment (baseline: 14.6 6 16.6
ng/ml vs 4 h: 21.7 6 23.8 ng/ml, P = .003), and this incre-
ment stayedstable in week 2 (21.5 6 17.5 ng/ml). BMI did
not increase significantly from baseline at week 2.
Baptista et al
40 explored a large sample of 60 schizo-
phrenic patients, treated in monotherapy with olanza-
pine, after switching from conventional AP, during
a period of 16 weeks. These investigators observed a sig-
nificant increment in SLL at week 8 (baseline: 7.1 6 6.8
ng/ml vs week 8: 9.2 6 7.9 ng/ml, P = .01) and no changes
in week 16 (6.1 6 6.1 pg/ml) vs baseline. In addition, sig-
nificant WG (P = .001) and BMI increase (P = .001) and
a positive correlation between leptin levels, BMI, and
WG were observed at week 8. During all measurements,
leptin levels were significantly higher in women than in
men (P = .001). However, these authors did not take
intoaccounttheeffectoftheinterruptionofconventional
antipsychotics on SLL, in addition to the subsequent ef-
fect of olanzapine, as also done by Popovic et al
41 In this
last study, modifications of SLL were evaluated in 13
schizophrenic patients treated with conventional AP
andswitchedtoclozapineorrisperidoneduring12weeks.
TheseinvestigatorsobservedasignificantincreaseinSLL
at week 12 comparing to baseline (baseline: 7.8 6 3.2
ng/mlvsweek12:15.8 64.0ng/ml,P<.05),buttheleptin
concentrations in 18 patients treated with conventional
AP were not different as compared with 20 healthy
controls (HCs).
Inalongitudinalstudy,Ederetal
42observedaconcom-
itant significant increase in SLL over baseline and
olanzapine-induced WG over baseline during an
8-week period in 10 schizophrenic inpatients, assigned
to monotherapy with olanzapine and compared with
healthy subjects (baseline: 2.5 6 2.4 ng/ml to week 8:
4.6 6 4.5 ng/ml, P = .03; weight: 68.8 6 11.3 to 72.1 6
10.5 kg, P = .001, vs baseline: 3.1 6 2.2 ng/ml to week
8: 2.7 6 2.0 ng/ml in HCs).
Ebenbichler and colleagues
43 determined whether WG
induced by treatment with olanzapine was associated
with changes in the soluble form of the leptin receptor
(sOB-R) and whether such modification of the biological
activity of leptin by sOB-R might contribute to WG. The
authors assessed 14 schizophrenic inpatients assigned to
a monotherapy with olanzapine during 10 weeks in com-
parison with HCs. Over a 10-week period, SLL increased
from 4.3 6 6.6 to 7.0 6 8.8 ng/ml (P = .002), while there
was no difference in the leptin level compared with the
control group (P = .175), and there was an increase in
BW (66.7 6 11.3 to 69.7 6 10.7 kg, P = .001).
In 2007, Atmaca et al
44 evaluated 21 schizophrenic
patients, enrolled in olanzapine monotherapy during 6
weeks and compared with 21 HCs. These investigators
reported that leptin levels were increased from the base-
line in the patients, while no difference was observed in
the control group during the same period (baseline: 5.9 6
1.5ng/mlvsweek6: 12.0 63.1ng/ml,P< .01,vsbaseline:
5.7 6 1.3 ng/ml vs week 6: 6.0 6 1.7 ng/ml in controls). In
addition, the mean change in weight for the olanzapine
group throughout 6 weeks was 6.8 6 3.0 kg (P < .05)
and the change in leptin levels correlated with the change
in BW (r = .61, P < .05) and in BMI (r = .55, P < .05).
In a previous longitudinal study, Atmaca et al
45 exam-
ined 45 inpatients with schizophrenia, treated by mono-
therapy with quetiapine (n = 15), olanzapine (n = 15), and
haloperidol (n = 15). The patients were evaluated at base-
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amarkedincreaseinleptinlevelsfortheolanzapinevsthe
quetiapine group (P < .05) and for the olanzapine vs the
haloperidol group (P < .01). The mean WG for the que-
tiapine, olanzapine, and haloperidol groups were 3.9, 8.4,
and 0.5 kg, respectively.
In addition, Krauss and colleagues
46 measured PLLs,
weight, and BMI at baseline and weekly (over 4 weeks) in
schizophrenic inpatients who received clozapine (n = 11),
olanzapine (n = 8), haloperidol (n = 13), and in an other
group of patients with various psychiatric disorders (n =
12) which did not receive any psychopharmacological
treatment. These investigators observed an increase
PLL associated with clozapine-induced WG, as soon
as the end of the first week after the beginning of the
treatment (baseline: 6.7 6 3.9 ng/ml vs week 1: 8.7 6 5.8
ng/ml and week 2: 9.4 6 6.0 ng/ml, P < .05). Olanzapine
also induced a similar effect (baseline: 6.1 6 4.2 ng/ml vs
week 2: 9.5 6 7.7 ng/ml, P < .05), whereas leptin level,
weight, and BMI remained stable in patient receiving
haloperidol or no psychopharmacological treatment.
In 2 studies, the effects on leptin concentration of 2
drugs were not analyzed separately. Zhang et al
47
assessed the effects of AP drug therapy on abdominal
fat deposition and on leptin and insulin secretion in 46
schizophrenic patients in their first episode treated
with risperidone (n = 30) and chlorpromazine (n = 15).
These patients were matched with 38 HCs. These authors
did not observe any significant difference in fasting PLL
between the control group and patients on admission
(11.07 6 11.39 vs 7.68 6 7.71 ng/ml) and a substantial el-
evation in PLL in the patient group after 10 weeks of
medication (21.61 6 17.13 ng/ml; P < .001, with signifi-
cant interactions with gender). In addition, significant
increases in all weight and fat indicators were observed
10 weeks after the beginning of the AP treatment in
the patient group (mean BW: 61.3 6 11.5 vs 56.7 6
11.4 kg before treatment, P < .05, and mean BMI:
22.2 6 3.4 vs 20.5 6 3.5 kg/m
2 at baseline, P < .01). Fi-
nally,Fitzgeraldetal
48reportedanincrementinPLLand
BMI in 22 schizophrenic women treated with risperidone
or olanzapine at week 12, compared with baseline (base-
line: 25.0 6 10.1 ng/ml vs week 12: 28.9 6 13.9 ng/ml, P =
.06, and for BMI, P = .03).
Six cross-sectional studies also evaluated the effects of
AP on leptin concentrations. In 2000, Melkersson et al
49
investigated the influence of olanzapine on SLL in 14
patients meeting the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, criteria for schizo-
phrenia or related psychosis and treated for 0.4 years
(0.2–1.4 years). The authors reported a median SLL of
24.2 ng/ml (range 6.7–39.5), and for all patients, SLL
were increased in 57%, and no correlation between leptin
and BMI was found. Later on Melkersson and Hulting
50
conducted a study in 47 patients with schizophrenia
and schizoaffective disorder receiving conventional AP
(n = 19) during 3.0 years (0.3–20.0 years), olanzapine
(n = 14) during 0.4 years (0.2–1.4 years), or clozapine
(n = 14) during 3.0 years (0.5–7.4 years). No significant
difference on SLL occurred among the 3 groups of
patients (conventional AP, median leptin level [MLL]:
20.1 lg/l [range 1.4–46.3]; clozapine, MLL: 10.3 lg/l
[range 2.4–46.9]; and olanzapine, MLL: 24.2 lg/l [range
6.7–39.5]). In addition, elevated BMI was found in 47%
of the patients in the conventional AP group, in 50% of
patientsintheclozapinegroup,andin57%ofthepatients
in the olanzapine group.
Herran et al
51 determined the effects of long-term
antipsychotic treatment (at least 6 months) on SLL of
59 outpatients with chronic schizophrenia treated with
AP (phenothiazines: n = 26, mean SLL = 11.30 6 7.92
ng/ml; haloperidol: n = 8, SLL = 10.74 6 9.30 ng/ml; olan-
zapine: n = 7, SLL = 26.60 6 20.02 ng/ml; clozapine: n = 5,
SLL=10.86 69.25ng/ml;risperidone:n=5,SLL=5.64 6
3.96 ng/ml compared with 59 HCs (11.5 6 10.2 ng/ml).
The SLL did not differ significantly between patients
and HC (P = .8). Differences in leptin levels were signif-
icant when comparingpatients taking AAP (P = .03), and
the levels were higher in females than in males both in
patients and in control group. Moreover, the authors
added that SLL in patients correlated significantly
with WG (P < .001) and showed a trend for an associa-
tion with BMI gains (P < .07).
Hagg et al
52 compared 87 schizophrenic patients and
related psychosis treated with clozapine (n = 41) during
2.8 years (2.4–3.3 years) as well as with conventional
AP (n = 62) during 8.7 years (7.1–10.2 years) to the gen-
eral population (n = 189). The authors reported an in-
crease of PLL; in separate multiple regression analyses,
leptin levels were significantly associated with clozapine
treatment in both men and women and with AP treat-
ment only in men (HC: men, 4.5 ng/ml; women, 13.7
ng/ml vs clozapine: men, 6.7 ng/l [P = .002]; women,
20.6 ng/ml [P = .023] vs conventional: men, 6.4 ng/ml
[P = .027]; women: 19.8 ng/ml [P = .11]). In addition, par-
tial correlation coefficients between leptin concentrations
and BMI controlling for sex and age were relatively high
in all groups (r = .67–.73).
Haupt and colleagues
53 indicated no evidence of mod-
ification in plasma leptin concentration in 72 patients
with schizophrenia compared with 124 HCs; the patients
were treated with olanzapine (n = 27), risperidone (n =
24), or conventional AP (n = 21) with medication dura-
tion greater than 3 months (mostly from 6 months to 2
years), and polytherapy was allowed (antidepressant,
mood regulators, conventional antipsychotic, and benzo-
diazepine). There was no interaction with BMI and treat-
ment or subject groups.
Finally, in 2007, Murashita et al
54 evaluated 15 schizo-
phrenic patients treated with risperidone monotherapy
for at least 6 months (r = .5–8.3 years) and compared
them with HCs (n = 25). They also measured glucose
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BMI were significantly higher in risperidone group (10.4
6 4.1 vs 6.4 6 4.2 ng/ml for HC, P = .0243, and 25.2 6 3.5
vs 22.8 6 2.1 kg/m
2 for HC, P = .015).
Ghrelin
More recently, ghrelin levels of antipsychotic-treated
patientswithschizophreniawereassessedin5prospective
and 3 cross-sectional studies (Table 2).
In a first prospective clinical study, Murashita et al
38
evaluated 7 Japanese patients with schizophrenia and
compared metabolic parameters before and after 6-
month administration of olanzapine. Both plasma total
ghrelin (baseline: 164.5 6 82.9 fmol/ml to week 26:
227.6 6 117.6 fmol/ml, P = .018) and active ghrelin
(baseline: 9.1 6 7.0 fmol/ml to week 26: 21.1 6 12.1
fmol/ml, P = .0057) were increased significantly after
the olanzapine treatment; the variation of BMI and
WG was not significant after 6 months of treatment.
Hosojima et al
11 recruited 13 patients with schizophre-
nia without medications for at least 4 weeks (6 patients
were AP naive) and receiving olanzapine for 4 weeks
in monotherapy. Serum bioactive (octanoylated) ghrelin
levels decreased significantly from baseline at week 4
(baseline: 92.6 6 62.6 pg/ml vs week 4: 61.2 6 42.8
pg/ml, P = .03).
Theisen et al
12 reported that bioactive serum ghrelin
level (SGL) did not differ significantly in 12 psychotic
patients during 10 weeks (baseline: 749 6 493 pg/ml vs
week 10: 777 6 394 pg/ml, P > .05).
Himmerich et al
55 reported on an open-labeled longi-
tudinal study of 52 patients free of medication for at least
1 week. Twenty-three schizophrenic patients received AP
among whom 6 received olanzapine or clozapine and 17
conventional AP, while 29 mood disorders patients re-
ceived antidepressants (13 patients receiving mirtazapine
or trimipramine). Total immunoreactive ghrelin levels
were measured at baseline and in the second week of
the treatments. Total ghrelin levels did not differ among
medication groups and did not relate to age or gender
(601 6 535.3 pg/ml for AAP group vs 502.18 6 279.9
pg/ml for conventional AP). BMI at the time of blood
measurement was significantly and inversely correlated
with ghrelin level. Finally, patients taking clozapine or
olanzapine showed a larger WG than did patients with
other AP medications.
Finally, Popovic et al
41 measured the modifications of
total SGL and BMI in 13 schizophrenic patients treated
with conventional AP and switched to clozapine or ris-
peridone during 12 weeks. The authors reported no mod-
ifications in SGL at weeks 4 and 12 as compared with
baseline and a significant increase in BMI (baseline:
947.5 6 140.3 pg/ml vs week 4: 890.1 6 72.7 pg/ml vs
week 12: 900.3 6 110.7 pg/ml, and for BMI, baseline:
22.4 6 0.9 kg/m
2 vs week 12: 23.1 6 0.8 kg/m
2, P <
.01); the total ghrelin concentrations in 18 patients
treated with conventional AP were not different as com-
pared with 20 HCs.
Three cross-sectional studies also evaluated the effects
of AP on ghrelin concentrations. Togo and colleagues
56
analyzed the effect of psychopharmacological treatment
Table 2. Circulating Ghrelin Level Modifications during AP Treatment in Psychotic Patients (prospective and cross-sectional studies)
Authors
Washout
Period (d) Drug
Number of
Patients
Duration
(wk)
Mean age
(y) 6 SD
Ghrelin
Modiﬁcations
Prospective studies
Murashita et al
38 NA OLZ 7 (3 w/4 m) 26 46.3 6 15.7 W26
a vs B: b
Hosojima et al
11 28 OLZ 13 (4 w/9 m) 4 37 (20–56) W4
a vs B: a
Theisen et al
12 NA CLZ 12 (6 w/6 m) 10 31 6 7.1 W10
a vs B: NS
Himmerich et al
55 7 OLZ/CLZ 6 (3 w/3 m) 2 49.83 6 11.02 W2
b vs B: NS
Others 17(8 w/9 m) 35.35 6 12.51 W2
b vs B: NS
Popovic et al
41 Switch CLZ/RISP 18 (9 w, 9 m) 12 28.8 6 1.6 W4
a, W12
a vs B: NS
Cross-sectional studies
Togo et al
56 OLZ 19 9 (4–68) 43.7 6 14.2 a
a vs HC
RISP 15 79 (4–294) 41.3 6 13.7 a
a vs HC
HC 18 35.3 6 6.5
Palik et al
57 CLZ 15 52 50.6 6 5.6 b
a vs HC
OLZ 14 b
a vs HC
RISP 15 b
a vs HC
QUET 12 b
a vs HC
HC 75 51.1 6 5.8
Murashita et al
54 RISP 15 (10 w/5 m) 26 40.8 6 11.8 b
a,b vs HC
HC 25
Note: Abbreviations are explained in the first footnote to table 1.
aOctanoylated ghrelin.
bTotal ghrelin.
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patients treated, respectively, with olanzapine (n = 19)
and risperidone (n = 15) for at least 4 weeks (4–294
weeks), with 18 HCs. The investigators reported signifi-
cant differences in serum bioactive octanoylated ghrelin
concentrations between patients treated with olanzapine
(50.5 6 23.7 pg/ml, P < .001) or risperidone (96.5 6 57
pg/ml, P < .001) vs HC (162.5 6 117.8 pg/ml).
While Palik et al
57 determined ghrelin levels in 56 AAP
patientstreatedcontinuouslyforatleast1year(clozapine
n = 15, olanzapine n = 14, risperidone n = 15, quetiapine
n = 12). BMI and carbohydrate metabolism were com-
pared with those of 75 HCs to evaluate the possible con-
tribution of ghrelin to a possible increase in appetite. The
active forms of SGLs in patients treated with AAP for at
least 1 year were similar among the 4 groups of treatment
and notably higher than in HCs (1333 6 659 vs 368 6 103
pg/ml, P < .0001). BMI of the total patient group was
significantly higher that the controls (29.3 6 7.2 vs
24.3 6 3.7 kg/m
2, P < .01). Patients had a much higher
ghrelin level with the same BMI than controls, suggesting
a possible abnormality in the regulation of ghrelin
secretion.
Finally, a third cross-sectional study (Murashita
et al
54) reported a significant increase in total ghrelin
(271.4 6 182.3 vs 159.2 6 57.4 fmol/ml, P = .0067), in ac-
tive ghrelin levels (24.2 6 20.8 vs 13.5 6 7.5 fmol/ml, P =
.0241), and in BMI (P = .01) in 15 schizophrenic patients
treated with risperidone monotherapy during 2.5 6 1.9
years (r = .5–8.3 years) as compared with 25 healthy
volunteers.
Synthesis
The aim of this review was to analyze the effects of an-
tipsychotic drugs on leptin and ghrelin circulating levels.
In all studies, leptin levels were measured in the early
morning in human plasma or serum in fasting patients.
The dosage was homogeneously performed in most of
the studies with commercial radioimmunoassay (RIA)
kits, an intraassay coefficient of variance (CV) varied
from 4.4% to 7% and an interassay CV from 5.2% to
10%. In 4 studies, ELISA method was used.
Women have more elevated PPLs than men,
22 in keep-
ing with the fact that women have more adipose tissues.
Surprisingly, only 3 of 19 prospective studies took this
gender effect into account when analyzing SLL. When
evaluated, a significant higher SLL was reported in
women in mean baseline values as well as in AAP-treated
subjects. However, in 2 cross-sectional studies and 1 pro-
spective, SLL did not differ between male and female
group.
A majority of the 22 studies, either prospective or
cross-sectional, focused their analysis on the effects of
clozapine and olanzapine on SLL. When prospective
studies are compared, a significant increase in SLLs
(from baseline or compared with HCs) occurs only
a few hours after the beginning of the treatment, seems
to peak between 6 and 10 weeks after, and remains some-
how elevated after that period up to several months.
(Some studies analyzed SLL in patients treated during
long periods.) These results are only partially confirmed
in cross-sectional studies with longer duration of cloza-
pine or olanzapine treatments (20–452 weeks). Indeed,
Herran et al
51 did not observe any difference in SLL
between patients treated with antipsychotic drugs
(clozapine, olanzapine, risperidone, and conventional
antipsychotics) compared with HCs, but the number of
patients was small.
One study (Sporn et al
58) was not included in table 1
because it evaluated SLL in psychotic children and could
not be easily compared with modifications as observed in
adult patients. In this study, however, increased values of
SLL were also observed in psychotic children vs HCs, 6
weeks after clozapine initiation.
In contrast to olanzapine and clozapine, in 3 of 4 stud-
ies (1 prospective and 3 cross-sectional), risperidone was
not effective on SLL.
In addition, SLL were not significantly modified in
patients treated with conventional neuroleptic treatment
who displayed less BW modifications when compared
with atypical ones. But it should be mentioned that
only a few studies (2 prospective
45,46 and 2 cross-
sectional
51,52) with a small number of patients addressed
this comparison.
Even if some authors regularly interviewed their
patients regarding appetite and food intake, no study
considered the feeding behavior of schizophrenic patients
treated with antipsychotic based on a sensitive and val-
idated food scale.
Only half of the studies reported the duration of wash-
out treatment before evaluating the effect of AAP on
SLL. When reported, washout duration varied from 3
days to 4 weeks and did not seem to affect leptin levels.
Only 2 studies
37,47 evaluated naive patients. Arranz and
colleagues
59 reported a higher increase in leptin concen-
trations in schizophrenia patients off AP treatment for
17.8 6 2.8 months than antipsychotic naive patients.
AAPdosesvariedfromsmalltohighdosesofthetreat-
ment. This did not seem to interact on the modulation of
leptin secretion (small doses of the drug are apparently
sufficient to induce this phenomenon).
Ten studies in treated psychotic patients assessed WG
and BMI and 3 studies demonstrated a significant posi-
tive correlation between BMI and SLL modifications;
this relationship was shown in lean and obese subjects
as well.
22
Ghrelin levels were measured in the early morning in
fasted patients and subjects in human serum by con-
ventional RIA methods, but only 3 studies indicated the
intraassay (5.3% to 8%) and interassay (7.8% to 13.6%)
CVs. As mentioned earlier, ghrelin in plasma or serum
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one and a desoctanoylated one which represents the bulk
of the activity but which is not able to bind to GHS-R
receptors. It is noteworthy that when both active and
total ghrelin are measured in the same studies, the
effects appear somehow clearer with the octanoylated
form. Different results for octanoylated and total ghrelin
levels may depend on the types of assay or RIA kits.
60
To date, only a few studies (n = 8) evaluated the effects
of AAP (olanzapine, clozapine, risperidone, and quetia-
pine) on ghrelin concentrations in schizophrenic
patients. In fact, when the duration of the antipsychotic
treatment is brief, from 2 to 9 weeks, there is a decrease
in serum-active ghrelin levels compared with baseline
and an increase during longer periods (26 and 52 weeks).
The latter occurred in the case of 4 different AAPs.
However, Himmerich et al
55 did not observe a variation
inSGLafter2weeksofolanzapineorclozapinetreatment
in 6 patients.
Periods of wash out were not systematically specified
except for 2 studies (eg, Hosojima et al
11 and Arranz
et al
59) in which all the patients included had been free
from medication for at least 1 week to 1 month. It
may be noted that it was also the only study reporting
a negative relation between BMI and SGL.
Leptin and ghrelin in olanzapine-treated patients in-
teract competitively (an increase on SLL and a decrease
in SGL
11,61). But this is not always observed and may
depend on the time course at which the measurements
are made.
43
Finally, and as for leptin, the relationships between
fasting plasma ghrelin concentrations and various an-
thropometric variables, such as the correlation between
SGLandBMI,wereseldomevaluated(exceptHimmerich
and Palik studies
55,57). When it was, this correlation
was negative.
Conclusion
The comparison of the literature allows to conclude that
an elevation on leptin levels of schizophrenic patients
during some AAP treatment (olanzapine and clozapine)
occurs very early after the onset of medication, and this
increase remains stable after a period of several weeks.
On the contrary, conventional antipsychotic treatments
do not interfere with leptin levels as seems also to be
the case with risperidone; but, for this last agent, only
afewstudiesareavailable.Inaddition,AAPmonotherapy
is not systematically evaluated, and other drugs such as
aripiprazole and amisulpride have not been studied as yet.
In contrast to leptin, a biphasic evolution on ghrelin
levels is observed, depending on the AAP treatment du-
ration: a decrease at earlier time intervals and an eleva-
tion in longer ones.
Surprisingly, body WG and correlations between pep-
tide levels and BMI were not systematically considered,
and to our knowledge, no study so far evaluated feeding
behavior during antipsychotic treatment.
Owing to continuing of increased prevalence of weight
modification and obesity in schizophrenia, future pro-
spective and follow-up studies in larger patients samples
are warranted to (1) determine the mechanistic basis of
these clinical effects and their potential for contributing
to the development of comorbid illness as well as (2)
study the hormonal responses to food intake, involving
ghrelin leptin and other satiety signals as insulin and adi-
nopectin, considering dynamic measurement and their
impact on weight during AAP treatment.
Future researches should carefully evaluate, before
and during AP treatment, the very complex aspects of
eating behavior which depends not only on hormonal
regulation but also on other factors such as emotion,
learning, and cognitive impairments. Possible correla-
tions between BMI and satiety signals should be taken
into account to identify those subjects who need special
clinical attention to prevent or minimize WG during AP
treatment. Monitoring of metabolic and feeding param-
eters may be useful in preventing metabolic abnormality,
thereby improving health and maintaining a good QOL
and the observance of APP treatment by the patients.
Funding
The Hearth and Artery Foundation to O.S.
References
1. Wetterling T. Bodyweight gain with atypical antipsychotics.
A comparative review. Drug Saf. 2001;24:59–73.
2. Taylor DM, McAskill R. Atypical antipsychotics and weight
gain—a systematic review. Acta Psychiatr Scand. 2000;101:
416–432.
3. Briffa D, Meehan T. Weight changes during clozapine treat-
ment. Aust N Z J Psychiatry. 1998;32:718–721.
4. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF,
Rosenheck R. Association of diabetes mellitus with use
of atypical neuroleptics in the treatment of schizophrenia.
Am J Psychiatry. 2002;159:561–566.
5. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-
induced weight gain and metabolic abnormalities: implica-
tions for increased mortality in patients with schizophrenia.
J Clin Psychiatry. 2004;65:(suppl 7): 4–18; quiz 19–20.
6. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR,
Wirshing WC. The effects of novel antipsychotics on glucose
and lipid levels. J Clin Psychiatry. 2002;63:856–865.
7. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-
induced weight gain: a comprehensive research synthesis.
Am J Psychiatry. 1999;156:1686–1696.
8. Brady KT. Weight gain associated with psychotropic drugs.
South Med J. 1989;82:611–617.
9. Zipursky RB, Gu H, Green AI, et al. Course and predictors
of weight gain in people with first-episode psychosis treated
with olanzapine or haloperidol. Br J Psychiatry. 2005;187:
537–543.
1197
Leptin and Ghrelin Levels in Patients with Schizophrenia10. Levin ED, Rezvani AH. Nicotinic-antipsychotic drug interac-
tions and cognitive function. EXS. 2006;98:185–205.
11. Hosojima H, Togo T, Odawara T, et al. Early effects of olan-
zapine on serum levels of ghrelin, adiponectin and leptin in
patients with schizophrenia. J Psychopharmacol. 2006;20:
75–79.
12. Theisen FM, Gebhardt S, Bromel T, et al. A prospective
study of serum ghrelin levels in patients treated with cloza-
pine. J Neural Transm. 2005;112:1411–1416.
13. Basile C, Giordano R, Vernaglione L, et al. Efficacy and
safety of haemodialysis treatment with the hemocontrol bio-
feedback system: a prospective medium-term study. Nephrol
Dial Transplant. 2001;16:328–334.
14. Casey DE, Zorn SH. The pharmacology of weight gain with
antipsychotics. J Clin Psychiatry. 2001;62:(suppl 7): 4–10.
15. Despres JP. Abdominal obesity as important component of
insulin-resistance syndrome. Nutrition. 1993;9:452–459.
16. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L,
Friedman JM. Positional cloning of the mouse obese gene
and its human homologue. Nature. 1994;372:425–432.
17. Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt
M. Radioimmunoassay of leptin in human plasma. Clin
Chem. 1996;42:942–946.
18. Baptista T. Body weight gain induced by antipsychotic drugs:
mechanisms and management. Acta Psychiatr Scand. 1999;
100:3–16.
19. Baptista T, Lacruz A, Angeles F, et al. Endocrine and meta-
bolic abnormalities involved in obesity associated with
typical antipsychotic drug administration. Pharmacopsychia-
try. 2001;34:223–231.
20. Fulton S, Pissios P, Manchon RP, et al. Leptin regulation
of the mesoaccumbens dopamine pathway. Neuron. 2006;51:
811–822.
21. Hommel JD, Trinko R, Sears RM, et al. Leptin receptor
signaling in midbrain dopamine neurons regulates feeding.
Neuron. 2006;51:678–680.
22. Considine RV, Considine EL, Williams CJ, et al. Evidence
against either a premature stop codon or the absence of obese
gene mRNA in human obesity. J Clin Invest. 1995;95:
2986–2988.
23. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human
and rodent: measurement of plasma leptin and ob RNA
in obese and weight-reduced subjects. Nat Med. 1995;1:
1155–1161.
24. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and
ghrelin in the regulation of food intake and body weight in
humans: a review. Obes Rev. 2007;8:21–34.
25. Jequier E. Leptin signaling, adiposity, and energy balances.
Ann N Y Acad Sci. 2002;967:379–388.
26. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H,
Kangawa K. Ghrelin is a growth-hormone-releasing acylated
peptide from stomach. Nature. 1999;402:656–660.
27. Tschop M, Weyer C, Tataranni PA, Devanarayan V,
Ravussin E, Heiman ML. Circulating ghrelin levels are
decreased in human obesity. Diabetes. 2001;50:707–709.
28. Anderson GH, Moore SE. Dietary proteins in the regulation
of food intake and body weight in humans. J Nutr. 2004;
134:974S–979S.
29. Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L,
Engel JA. Ghrelin administration into tegmental areas
stimulates locomotor activity and increases extracellular
concentration of dopamine in the nucleus accumbens. Addict
Biol. 2007;12:6–16.
30. Rindi G, Savio A, Torsello A, et al. Ghrelin expression
in gut endocrine growths. Histochem Cell Biol. 2002;117:
521–525.
31. Formiguera X, Canton A. Obesity: epidemiology and clinical
aspects. Best Pract Res Clin Gastroenterol. 2004;18:
1125–1146.
32. Ukkola O, Poykko SM, Antero Kesaniemi Y. Low plasma
ghrelin concentration is an indicator of the metabolic syn-
drome. Ann Med. 2006;38:274–279.
33. Langenberg C, Bergstrom J, Laughlin GA, Barrett-Connor
E. Ghrelin and the metabolic syndrome in older adults.
J Clin Endocrinol Metab. 2005;90:6448–6453.
34. Bromel T, Blum WF, Ziegler A, et al. Serum leptin levels
increase rapidly after initiation of clozapine therapy. Mol
Psychiatry. 1998;3:76–80.
35. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M.
Pronounced early increase in circulating leptin predicts
a lower weight gain during clozapine treatment. J Clin
Psychopharmacol. 2002;22:424–426.
36. Kivircik BB, Alptekin K, Caliskan S, et al. Effect of clozapine
on serum leptin, insulin levels, and body weight and compo-
sition in patients with schizophrenia. Prog Neuropsychophar-
macol Biol Psychiatry. 2003;27:795–799.
37. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr,
Lieberman JA, Harp JB. Effect of olanzapine on body com-
position and energy expenditure in adults with first-episode
psychosis. Am J Psychiatry. 2005;162:118–123.
38. Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases
plasma ghrelin level in patients with schizophrenia. Psycho-
neuroendocrinology. 2005;30:106–110.
39. Wang HC, Chen PS, Lee IH, Yang YK, Yeh TL, Lu RB.
Rapid leptin elevation after initiation of olanzapine? Neuro-
psychobiology. 2006;54:182–185.
40. Baptista T, Davila A, El Fakih Y, et al. Similar frequency of
abnormal correlation between serum leptin levels and BMI
before and after olanzapine treatment in schizophrenia. Int
Clin Psychopharmacol. 2007;22:205–211.
41. Popovic VM, Doknic NM, Pekic AS, et al. Changes in neuro-
endocrine and metabolic hormones induced by atypical anti-
psychotics in normal-weight patients with schizophrenia.
Neuroendocrinology. 2007;85:249–256.
42. Eder U, Mangweth B, Ebenbichler C, et al. Association of
olanzapine-induced weight gain with an increase in body
fat. Am J Psychiatry. 2001;158:1719–1722.
43. Ebenbichler C, Laimer M, Kranebitter M, et al. The soluble
leptin receptor in olanzapine-induced weight gain: results
from a prospective study. Schizophr Res. 2005;75:143–146.
44. Atmaca M, Tezcan E, Ustundag B. Plasma nitric oxide and
leptin values in patients with olanzapine-induced weight
gain. J Psychiatry Res. 2007;41:74–79.
45. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin
and triglyceride levels in patients on treatment with atypical
antipsychotics. J Clin Psychiatry. 2003;64:598–604.
46. Kraus T, Haack M, Schuld A, et al. Body weight and leptin
plasma levels during treatment with antipsychotic drugs.
Am J Psychiatry. 1999;156:312–314.
47. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of
antipsychotics on fat deposition and changes in leptin and in-
sulin levels. Magnetic resonance imaging study of previously
untreated people with schizophrenia. Br J Psychiatry.
2004;184:58–62.
48. Fitzgerald PB, Scaffidi A, Morris MJ, de Castella AR,
KulkarniJ.Therelationshipofchangesinleptin,neuropeptide
1198
O. Sentissi et al.Y and reproductive hormones to antipsychotic induced weight
gain. Hum Psychopharmacol. 2003;18:551–557.
49. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of
insulin, leptin, and blood lipids in olanzapine-treated patients
with schizophrenia or related psychoses. J Clin Psychiatry.
2000;61:742–749.
50. Melkersson KI, Hulting AL. Insulin and leptin levels in
patients with schizophrenia or related psychoses—a compar-
ison between different antipsychotic agents. Psychopharma-
cology (Berl). 2001;154(2):205–212.
51. Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT,
Alvarez C, Vazquez-Barquero JL. Effects of long-term
treatment with antipsychotics on serum leptin levels. Br J
Psychiatry. 2001;179:59–62.
52. Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T. Leptin
concentrations are increased in subjects treated with
clozapine or conventional antipsychotics. J Clin Psychiatry.
2001;62:843–848.
53. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA,
Newcomer JW. Plasma leptin and adiposity during antipsy-
chotic treatment of schizophrenia. Neuropsychopharmacology.
2005;30:184–191.
54. Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid me-
tabolism of long-term risperidone monotherapy in patients
with schizophrenia. Psychiatry Clin Neurosci. 2007;61:54–58.
55. Himmerich H, Fulda S, Kunzel HE, et al. Ghrelin plasma lev-
els during psychopharmacological treatment. Neuropsychobi-
ology. 2005;52:11–16.
56. Togo T, Hasegawa K, Miura S, et al. Serum ghrelin con-
centrations in patients receiving olanzapine or risperidone.
Psychopharmacology (Berl). 2004;172:230–232.
57. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Correlation
of serum ghrelin levels with body mass index and carbohy-
drate metabolism in patients treated with atypical antipsy-
chotics. Diabetes Res Clin Pract. 2005;68:(suppl 1): S60–S64.
58. Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates
of clozapine-induced weight gain in psychotic children: an
exploratory study. J Am Acad Child Adolesc Psychiatry.
2005;44:925–933.
59. Arranz B, Rosel P, Ramı ´rez N, et al. Insulin resistance and
increased leptin concentrations in noncompliant schizophre-
nia patients but not in antipsychotic-naive first-episode
schizophrenia patients. J Clin Psychiatry. 2004;65:1335–1342.
60. Hotta M, Ohwada R, Katakami H, Shibasaki T, Hizuka N,
Takano K. Plasma levels of intact and degraded ghrelin and
their responses to glucose infusion in anorexia nervosa.
J Clin Endocrinol Metab. 2004;89:5707–5712.
61. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin
in the central regulation of feeding. Nature. 2001;409:
194–198.
1199
Leptin and Ghrelin Levels in Patients with Schizophrenia